HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Ixoten therapy in malignant lymphomas].

Abstract
Clinical experience with Ixoten (trofosfamide), a derivative of cyclophosphamide, is reported in 29 patients with malignant lymphomas. Daily doses of 150-300 mg p.o. and 6.000-200.000 mg total dose respectively, resulted in an 80% complete or partial remission. In addition to a dose dependent haematotoxicity, other side effects (gastrointestinal and/or hair loss) were almost negligible.
AuthorsP Pötzi, P Aiginger, J Kühböck
JournalActa medica Austriaca (Acta Med Austriaca) Vol. 6 Issue 5 Pg. 247-9 ( 1979) ISSN: 0303-8173 [Print] Austria
Vernacular TitleIxoten-Therapie bei malignen Lymphomen.
PMID400215 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Cyclophosphamide
  • trofosfamide
Topics
  • Adult
  • Aged
  • Cyclophosphamide (analogs & derivatives, therapeutic use)
  • Dose-Response Relationship, Drug
  • Female
  • Hodgkin Disease (drug therapy)
  • Humans
  • Leukemia, Lymphoid (drug therapy)
  • Lymphoma (drug therapy)
  • Lymphoma, Follicular (drug therapy)
  • Lymphoma, Non-Hodgkin (drug therapy)
  • Male
  • Middle Aged
  • Plasmacytoma (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: